Elona Baum from CIRM to Speak at the Stem Cell Summit – April 2013 in Boston, MA

Printer-friendly versionPDF version

Elona Baum, General Counsel & Vice President of Business Development at CIRM to Present at the Stem Cell Summit 2013 (Apr 29-30, 2013 in Boston, MA)

Boston, CA, China., March 12, 2013 - (PressReleasePoint) - Elona Baum, General Counsel & Vice President of Business Development at the California Institute of Regenerative Medicine will present on “Strategic Partnerships in Stem Cell Research & Regenerative Medicine” at the Stem Cell Summit 2013 (Apr 29-30, 2013 in Boston, MA)
 
This discussion will cover partnering strategies in the regenerative medicine and stem cell field, including early pharma investments and current trends. In addition, Elona Baum will address the CIRM Strategic Partnership Funding Initiative.
 
Elona Baum is the General Counsel and Vice President of Business Development for the California Institute for Regenerative Medicine (CIRM).  She is an experienced attorney with more than 20 years of practice, mostly in the life sciences and drug development field.  As a member of CIRM’s executive team, Ms. Baum is responsible for the strategic initiatives of the agency, as well as overall management of the legal function. 
 
The 2013 Stem Cell Summit includes two parallel tracks. This summit provides cutting-edge information on developments in all areas of stem cell research including the biology, medicine, applications, regulations, and commercialization of stem cells. 


Track A: Stem Cell Research & Regenerative Medicine:
Joint Session: Funding Opportunities 
Joint Session: Regulatory Guidance & Updates
Session: Advances in iPS & ES Cells
Session: Advances in Adult Stem Cells
Session: New Paradigms for Cell Therapy
 
Track B: Stem Cell Commercialization & Partnering:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Update
Session: Novel Technologies in Stem Cell Research
Session: Overcoming Challenges in Clinical Development
Session: Commercialization: Bringing Therapeutics to Market
Session: Partnerships & Acquisitions
 
 
Summit Agenda: www.gtcbio.com/stemcellsummit/agenda
Summit Speaker List: www.gtcbio.com/stemcellsummit/speakers
For more information, please visit www.gtcbio.com